Spes Immunotherapeutics Selected for ATMP Catalyst Program to Accelerate Advanced Therapy Innovation

Barcelona, June 2025 – Spes Immunotherapeutics has been chosen to participate in the prestigious ATMP Catalyst initiative, a collaborative acceleration program jointly driven by Ajuntament de Barcelona, Biocat, and Generalitat de Catalunya. This initiative aims to rapidly advance Advanced Therapy Medicinal Products (ATMPs) and establish Catalonia as a leading international hub for innovative healthcare solutions.

Spes Immunotherapeutics was selected based on its cutting-edge personalized immunotherapy platform that addresses significant unmet medical needs in oncology, particularly acute leukemia. The ATMP Catalyst program provides specialized mentorship, tailored regulatory and strategic guidance, and direct access to a robust network of clinical and industrial partners, positioning Spes Immunotherapeutics to accelerate its promising therapies towards clinical application.

"We are deeply honored to join the ATMP Catalyst initiative," stated Dr. Ricky Tirtakusuma, Co-founder and Head of R&D. "This recognition highlights the transformative potential of our immunotherapies and provides critical support in navigating the complexities of ATMP development."

"Being part of this program not only validates our scientific approach but also connects us directly to a community of experts committed to innovation in advanced therapies," commented Gioele Stoffel, Co-founder and Head of Business. "We’re eager to leverage these resources to expedite the journey of our therapies from research to patients."

Participation in the ATMP Catalyst is expected to significantly enhance Spes Immunotherapeutics’ capabilities in regulatory planning, product development, and market entry strategies, ensuring swift progress toward clinical and commercial milestones.

For further details about the ATMP Catalyst program, visit: https://www.biocat.cat/en/sala-de-premsa/notes-de-premsa/ajuntament-biocat-generalitat-impulsa-atmp-catalyst